• Ethics and Safety is of the upmost importance to the TAIN consortium, particularly when developing treatments for very young children. The WP6 partners are Diurnal Ltd and Charité - Universitätsmedizin Berlin, who will ensure that the work of the TAIN consortium meets the highest safety and ethical standards.

  • Work Package 6

    The strategic objective of WP6 is to have clear responsibility for, and to monitor all ethical aspects of, the clinical trials and to organise short- and long-term monitoring in order to identify any potential adverse drug reactions.

  • Work Package 6

    • 6.1 Creation of an independent ethics and safety monitoring board
    • 6.2 Develop parent and patient consent forms
    • 6.3 Pharmacovigilance and monitoring
  • Work Package 6

    Deliverables
    Status
    Ethics Advisory Board and Independent Safety Monitoring Board
     
    Systematic Literature Review
     
    Ethical Issues and Regulation Report
     
    Local Ethics Committee Approvals
     
    Six Monthly Reviews